What is the classification for raloxifene?
Raloxifene is in a class of medications called selective estrogen receptor modulators (SERMs). Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone.
What drug classification is Evista?
Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs.
Is raloxifene A bisphosphonates?
The bisphosphonate alendronate and the selective estrogen receptor modulator (SERM) raloxifene are among the most popular antiresorptive agents for the prevention and treatment of postmenopausal osteoporosis6,7.
What is the mechanism of action for raloxifene?
The mechanism of action of raloxifene occurs through binding to estrogen receptors. This binding results in activation of estrogenic pathways (estrogen-agonistic effect) and blockade (estrogen-antagonistic effect) in tissues that express estrogen receptors.
Is raloxifene an agonist or antagonist?
Raloxifene, a selective estrogen receptor (ER) modulator, is a mixed estrogen agonist/antagonist that has been shown to prevent osteoporosis and breast cancer in women.
What is raloxifene other names?
Evista is the trade name for Raloxifene. In some cases, health care professionals may use the trade name Evista when referring to the generic drug name Raloxifene. Drug type: Evista is a hormone therapy. This medication is classified as a Selective Estrogen Receptor Modulator (SERM).
Is raloxifene generic for Evista?
Generic name: Raloxifene Evista is the trade name for Raloxifene. In some cases, health care professionals may use the trade name Evista when referring to the generic drug name Raloxifene. Drug type: Evista is a hormone therapy. This medication is classified as a Selective Estrogen Receptor Modulator (SERM).
What is the difference between tamoxifen and raloxifene?
Tamoxifen is used mainly to treat hormone receptor-positive breast cancer (breast cancer with cells that have estrogen and/or progesterone receptors on them). Raloxifene is used mostly to prevent and treat osteoporosis (very weak bones) in post-menopausal women.
What are the side effects of Evenity?
Common side effects of Evenity include:
- joint pain,
- headache,
- muscle spasms,
- swelling of extremities,
- weakness,
- neck pain,
- insomnia,
- numbness and.
What is raloxifene prescribed for?
Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break. Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause.
Is raloxifene an estrogen agonist?
Raloxifene is a selective estrogen receptor modulator that produces both estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue.
Does raloxifene block estrogen?
Raloxifene acts like the female sex hormone oestrogen, although it isn’t a hormone. It copies how the oestrogen works and is able to increase the thickness (density) of the bone to prevent and treat bone thinning. To prevent breast cancer raloxifene is able to block the hormone oestrogen.
What is the generic name for raloxifene?
Raloxifene. Generic name: raloxifene (ra LOX i feen) Brand name: Evista. Dosage forms: oral tablet (60 mg) Drug class: Hormones / antineoplastics, Selective estrogen receptor modulators. Medically reviewed by Drugs.com on March 30, 2020. Written by Cerner Multum. Uses. Warnings.
What is the mechanism of action of raloxifene?
Raloxifene is a second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. Raloxifene is an Estrogen Agonist/Antagonist.
Is raloxifene an estrogen antagonist or antagonist?
Raloxifene is a selective estrogen receptor modulator (SERM) and therefore a mixed agonist–antagonist of the estrogen receptor (ER). It has estrogenic effects in bone and antiestrogenic effects in the breasts and uterus. Raloxifene was approved for medical use in the United States in 1997.
How does raloxifene treat osteoporosis?
Raloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. Raloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue.